Basket | Login


EPAD exhibits at AAIC 2019

Thursday 18 July 2019

Members of the European Prevention of Alzheimer’s Dementia (EPAD) project attended the Alzheimer's Association International Conference (AAIC) held on 14-18 July. They travelled to Los Angeles (US) from across Europe for the biggest event in dementia research. This is the second year that the team exhibited the EPAD studies with its EPAD branded green and white booth in the exhibition area. They were delighted that more than 350 people stopped by at the EPAD booth to learn more about the project and discuss further topics such as the EPAD data access process, the Longitudinal Cohort Study (LCS) and the Proof of Concept (PoC) study. It was also a great opportunity to meet many current and future EPAD collaborators.  EPAD also had a business suite at the exhibition area where many engaging meetings with potential interventional owners and other world experts on Alzheimer’s disease prevention took place. Altogether, the conversations they had at the booth and the business suite generated a rich exchange of ideas and they are excited that various collaborations are being considered.

At AAIC 2019, the aim of the EPAD booth was twofold. The first aim was to showcase the EPAD PoC trial platform and engage the pharmaceutical and biotechnology industry. To support this, a new high quality animated video was created to highlight the key benefits of the EPAD approach to develop drugs for Alzheimer’s disease (you can watch it here). The second aim was to show all the benefits that EPAD has to offer to the scientific community. In order to do so, the EPAD booth included an interactive screen on which attendees could browse their topics of interest including the LCS and PoC studies, the EPAD Academy, the data access process and upcoming data batches, disease modelling, the statistical study design and interviews and testimonials of many members and collaborators.

Additionally, the EPAD team had two oral presentations at AAIC on different aspects of the project. Both generated a great deal of interest from researchers outside the project:

  • Associations between Multimorbidity and CSF Amyloid: Cross-Sectional Analysis of the European Prevention of Alzheimer's Dementia (EPAD) Cohort from Lucy Stirland (UEDIN)
  • Prescreening for European Prevention of Alzheimer Dementia (EPAD) Trial-Ready Cohort: Impact of AD risk factors and recruitment settings from Lisa Vermunt (VUmc).

The EPAD project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.